Parallel Advisors’s XBiotech XBIT Stock Holding History

Parallel Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-147	Closed	-$2K	–	2508
2019 Q3	$2K	Hold	147	–	–	﹤0.01%	2214
2019 Q2	$1K	Buy	+147	New	+$1.28K	﹤0.01%	2258

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Parallel Advisors's XBIT Position: Q4 2019 in Review

Parallel Advisors sold out of XBiotech (XBIT) in Q4 2019, closing a stake of 147 shares — an estimated $2K sold.

Parallel Advisors first reported a position in XBIT in Q2 2019 and held it in 2 quarters. The position peaked at $2K in Q3 2019. 60 funds tracked by Wall St. Rank hold XBIT as of Q4 2019.

Parallel Advisors reported no remaining XBiotech position as of Q4 2019 after selling out during the quarter.
Parallel Advisors sold 147 XBiotech shares in Q4 2019, an estimated $2K.
Parallel Advisors first reported a position in XBiotech in Q2 2019 and held it in 2 quarters.
Parallel Advisors's XBiotech position peaked at $2K in Q3 2019.
60 funds tracked by Wall St. Rank held XBiotech as of Q4 2019.

Based on Parallel Advisors's 13F filing for Q4 2019, filed 30 Jan 2020.